This study offers one of the largest multicentric analyses of advanced sarcoma patients treated with immune checkpoint inhibitors (ICIs), highlighting the predictive value of histological subtype and identifying potential roles for specific molecular alterations, such as NF1. Here, NF1 is linked to sarcoma.